*Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD;
†Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD;
‡Lions VisionGift, Portland, OR;
§Eversight, Ann Arbor, MI;
¶Saving Sight, Kansas City, MO;
‖VisionFirst, Carmel, IN; and
**CorneaGen, Seattle, WA.
Correspondence: Divya Srikumaran, MD, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Odenton, 1106 Annapolis Rd, Odenton, MD 21113 (e-mail: [email protected]).
Supported by the National Institutes of Health (P30EY001765, Wilmer Biostats Core).
M. B. Engstrom is employed by Lions VisionGift. C. G. Stoeger is the CEO of Lions VisionGift. C. McClory is employed by Eversight. M. S. Titus is employed by Eversight. P. Johnson is the Director of Quality Improvement and Regulatory Affairs for Saving Sight. K. B. Johnston is employed by VisionFirst. T. Fischer is the President/CEO of VisionFirst. L. K. Brooks is employed by VisionFirst. M. M. Montoya is the President and CEO of CorneaGen. D. Srikumaran is a consultant for Alcon and receives grant support from the National Eye Institute and American Academy of Ophthalmology/Hoskins Center unrelated to this work. The remaining authors have no conflicts of interest to disclose.
Preliminary data from this article were accepted for a poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) Meeting; May 2020; and a paper presentation for the World Cornea Congress Meeting; May 2020. Both meetings were canceled because of coronavirus disease 2019 (COVID-19)–related restrictions.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.corneajrnl.com).
